Diabetes and Hypertension
Diabetes and Hypertension
Part of NephTimes Diseases and Conditions
Advertisement
Freely FilteredDiabetes and Hypertension | April 22, 2024
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Listen Now
Charlotte RobinsonChronic Kidney Disease | April 15, 2024
Kavita Mistry and Marcelle Tuttle will be the American Kidney Fund 2024 Clinical Scientist in Nephrology Fellows.
Charlotte RobinsonDiabetes and Hypertension | April 1, 2024
SGLT-2is are associated with reduced risk of mortality in patients with type 2 diabetes and acute kidney disease.
Charlotte RobinsonDiabetes and Hypertension | March 29, 2024
Medicare Part D spending on GLP-1 drugs has soared to $5.7 billion, straining Medicare spending.
Charlotte RobinsonDiabetes and Hypertension | March 29, 2024
Current practice guidelines do not address dietary management specific to diabetic kidney disease (DKD).
Charlotte RobinsonDiabetes and Hypertension | March 8, 2024
AstraZeneca has removed tozorakimab from its phase 2 pipeline for diabetic kidney disease.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Patients with diabetic kidney disease face increased risk of end-stage kidney disease and dialysis.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Albuminuria, hypertension, declining kidney function, and an increase in cardiovascular risk are all hallmarks of DKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Strategies for the accurate evaluation of the risk of fragility fractures in elderly patients in the early stages of DKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Compared with DPP4 inhibitors, SGLT2 inhibitors were associated with a lower risk for the kidney-specific outcome.
Victoria SochaDiabetes and Hypertension | February 5, 2024
In patients with type 2 diabetes mellitus, identifying nondiabetic kidney disease is crucial in delaying progression of CKD.
Victoria SochaChronic Kidney Disease | February 5, 2024
Development and validation of a model to predict future trajectories in eGFR in adults with type 2 diabetes and CKD.
Victoria SochaChronic Kidney Disease | February 5, 2024
A 2004 landmark study demonstrated an association between chronic kidney disease and an increased risk of CV events.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Early diagnosis of CKD and active management can slow progression and improve outcomes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Using antihypertensive medication in patients with persistent treatment-resistant hypertension concurrent with CKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Patients with type 2 diabetes without other comorbidity are often treated with metformin as antiglycemic therapy.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Previous studies have documented associations between chronic kidney disease (CDK), obesity, and metabolic syndrome.
Victoria SochaDiabetes and Hypertension | February 5, 2024
There was no association between systolic IABPD and eGFR in the multiple linear regression model.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Examining the occurrence of proteinuria and impairment in renal function in a cohort of living hypertensive kidney donors.
Advertisement
Advertisement
Advertisement
Latest News

April 24, 2024